For type 2 diabetes management , NICE guidance (NG28) recommends GLP-1 agonists as second- or third-line therapy when metformin and other oral agents provide inadequate glycaemic control, or as an alternative to insulin in appropriate patients
However, it is not approved for insomnia
Your purchase helps create local jobs, strengthens our economy, and fosters community well-being
Dieterich W, Zopf Y
Data extraction Information on the baseline characteristics of the samples enrolled included age, gender, proportion of patients with T2D, baseline BMI, TBWL%, waist circumference, body composition, proportion of patients achieving at least 5%, 10%, 15%, 20%, and 25% body weight reduction, remission or improvement/resolution of obesity-related complications, SAE, mortality, MACE, FPG, HbA1c, lipid profile, estimated glomerular filtration rate (eGFR), creatinine, albuminuria, mental health parameters and QoL